Johnson and Johnson have reached out to other coronavirus vaccine makers to join a study on the risk of blood clots, the Wall Street Journal (WSJ) reported Friday, citing a number of people.
Johnson and Johnson reached out to other coronavirus vaccine makers to join a study on the risk of blood clots, the Wall Street Journal (WSJ) reported Friday, citing several people.
Johnson and Johnson sought to build an industry-wide alliance between the four vaccine manufacturers for benefits and risky communication and to address public concerns, sources told WSJ. It ched in by issuing a joint statement on the formation of expert panels and the issue of blood clotting
Pfizer and Moderner officials rejected Johnson and Johnson’s offer, saying their vaccines had arrived safely and that regulators were investigating the cause of the already reported blood clots, sources said.
An organization has expressed concern that Johnson and Johnson’s reputation could be tarnished by their involvement in the research, people familiar with the matter told WSJ.
Six women in the U.S. who received the Johnson and Johnson vaccine had blood clots and one died, out of more than seven million people across the country to be given the dose, U.S. government officials said.
AstraZeneca has provided the vaccine in more than 20 countries in recent weeks due to similar blood clotting concerns, but Johnson and Johnson have agreed to the study – according to sources.
U.S. health officials say the Pfizer and Moderner shots did not cause people in the U.S. to express blot-clot concerns.
Drug makers, usually rivals and fierce rivals, rallied in unprecedented fashion last year to tackle the coronavirus, but the WSJ report underscores the limits of their solidarity.
Some vaccine manufacturers are now facing safety issues in RAB jobs at record times, as those companies take the fine line between investigating risks and stopping people from getting vaccinated.
Health officials in several European countries have already banned the use of the AstraZeneca vaccine after a number of people who received shoots in early March had problems with blood clots.
The United Kingdom has also advised against the use of AstraZeneca shots in people under the age of 30, and European regulators are examining the Johnson and Johnson vaccine.
Sources said Johnson and Johnson began reaching out to other vaccine manufacturers last week, raising widespread concerns across Europe after expressing concern about the safety of its shots, sources said.
U.S. health authorities earlier this week recommended that Johnson and Johnson stop using single-dose shots while investigating.
To other vaccine makers, Johnson and Johnson proposed forming a panel to review all blood clotting reports and evaluate the report using the same methodology, a person familiar with the discussion told WSJ.
Astrageneca was keen to come together for an industry-wide investigation into vaccinated and untreated groups to better understand the cause of clots, the report said.
Following a U.S. warning about a blood clotting case this week, Pfizer’s chief executive, Albert Baulah, said on Twitter that his company was increasing vaccine production to help Johnson and Johnson’s dose be damaged.
Despite giving more than a million doses internationally over the past month, no link has been found between his shots and blood clots, Modarna said.